BridgeMD
New treatment option for Esophageal Squamous Cell Carcinoma
Official title Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
ClinicalTrials.gov ID: NCT06602843
What this study is testing
- What it's testing
- The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Ages 18-75;
- Radical operation for esophageal cancer;
- Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone...
- More than or equal to 12 lymph nodes were surgically removed;
- Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy;
You likely can't join if
- Less than 18 years old, more than 75 years old;
- did not receive radical resection of esophageal cancer, including palliative resection;
- Postoperative pathology showed non-esophageal squamous cell carcinoma;
- After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB...
- Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy;
- The patient or family member did not sign the informed consent.
See the full eligibility criteria
- Ages 18-75;
- Radical operation for esophageal cancer;
- Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation were performed, and the...
- More than or equal to 12 lymph nodes were surgically removed;
- Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy;
- Informed consent signed by patient or family member.
- Less than 18 years old, more than 75 years old;
- did not receive radical resection of esophageal cancer, including palliative resection;
- Postoperative pathology showed non-esophageal squamous cell carcinoma;
- After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB (AJCC eighth edition staging standard); e. Less than 12 lymph nodes...
- Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy;
- The patient or family member did not sign the informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.